PCART7-CD3

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NamePCART7-CD3
Drug Alias NameAnti-CD3 + anti-CD7 CAR T-cell therapy (MediSix Therapeutics/National University of Singapore)anti-CD3/CD7 PEBL CAR T-cellsPCART7-CD3
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionT-cell antigen CD7 modulatorsT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3T-cell antigen CD7
Therapy Area/IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingapore
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesNational University Of Singapore
China Registration ClassN/A

Develop Information

Active CompaniesMediSix TherapeuticsNational University Of Singapore
Inactive CompaniesN/A
Active IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A